MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

4.38

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.28

Max

4.43

Galvenie mērījumi
By Trading Economics
Ienākumi	-12M -27M
Pārdošana	-5.3M 663K
P/E Sektora vidējais	22.5 66.418
Peļņas marža	-3,998.492
Darbinieki	69
EBITDA	-13M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+211.39% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-193M 951M
Iepriekšējā atvēršanas cena	4.38
Iepriekšējā slēgšanas cena	4.38

Ziņu noskaņojums

By Acuity

50%

154 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. apr. 23:25 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026. g. 13. apr. 22:45 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026. g. 13. apr. 18:03 UTC

Peļņas

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026. g. 13. apr. 23:58 UTC

Peļņas

Review & Preview: Earnings Time -- Barrons.com

2026. g. 13. apr. 23:49 UTC

Tirgus saruna

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026. g. 13. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026. g. 13. apr. 23:20 UTC

Tirgus saruna

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026. g. 13. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026. g. 13. apr. 21:26 UTC

Galvenie ziņu notikumi

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026. g. 13. apr. 21:23 UTC

Peļņas

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026. g. 13. apr. 21:16 UTC

Peļņas

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026. g. 13. apr. 19:59 UTC

Tirgus saruna

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026. g. 13. apr. 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026. g. 13. apr. 19:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Precious Metals Market Talk on April 9

2026. g. 13. apr. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026. g. 13. apr. 18:43 UTC

Tirgus saruna

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

211.39% augšup

Prognoze 12 mēnešiem

Vidējais 13.67 USD 211.39%

Augstākais 17 USD

Zemākais 11 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

154 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.